• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

目前正在进行临床试验,以测试免疫疗法与放射疗法相结合的效果。

Current clinical trials testing the combination of immunotherapy with radiotherapy.

机构信息

Department of Radiation Oncology, Weill Cornell Medicine, 525 East 68th Street, New York, NY 10065 USA.

Department of Radiation Oncology, Weill Cornell Medicine, 525 East 68th Street, New York, NY 10065 USA ; Department of Radiation Oncology, Stich Radiation Center, 525 East 68th Street, New York, NY 10065 USA.

出版信息

J Immunother Cancer. 2016 Sep 20;4:51. doi: 10.1186/s40425-016-0156-7. eCollection 2016.

DOI:10.1186/s40425-016-0156-7
PMID:27660705
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5028964/
Abstract

Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion in the number of clinical trials harnessing radiation to enhance antitumor immunity. If positive, results of these trials will lead to a paradigm shift in the use of radiotherapy. In this review, we discuss the rationale for trials combining radiation with various immunotherapies, provide an update of recent clinical trial results and highlight trials currently in progress. We also address issues pertaining to the optimal incorporation of immunotherapy with radiation, including sequencing of treatment, radiation dosing and evaluation of clinical trial endpoints.

摘要

越来越多的证据表明,辐射是一种免疫刺激物,能招募免疫介质,在辐射场内外引发抗肿瘤反应。利用辐射增强抗肿瘤免疫的临床试验数量迅速增加。如果这些试验的结果是积极的,将导致放疗使用模式的转变。在这篇综述中,我们讨论了将辐射与各种免疫疗法相结合的临床试验的原理,提供了最新的临床试验结果,并强调了目前正在进行的试验。我们还讨论了与免疫疗法与放疗相结合相关的问题,包括治疗的顺序、放疗剂量和临床试验终点的评估。

相似文献

1
Current clinical trials testing the combination of immunotherapy with radiotherapy.目前正在进行临床试验,以测试免疫疗法与放射疗法相结合的效果。
J Immunother Cancer. 2016 Sep 20;4:51. doi: 10.1186/s40425-016-0156-7. eCollection 2016.
2
A narrative review of combining radiation and immunotherapy in gastroesophageal cancers.关于食管癌和胃癌中放疗与免疫治疗联合应用的叙述性综述。
Transl Cancer Res. 2021 May;10(5):2586-2595. doi: 10.21037/tcr-20-2210.
3
Harnessing the abscopal effect for gastrointestinal malignancies in the era of immunotherapy.在免疫治疗时代利用远隔效应治疗胃肠道恶性肿瘤。
J Gastrointest Oncol. 2023 Jun 30;14(3):1613-1625. doi: 10.21037/jgo-23-105. Epub 2023 Jun 2.
4
[Combining radiotherapy with immunotherapy for urological malignancies].[放射治疗与免疫治疗联合用于泌尿生殖系统恶性肿瘤]
Urologe A. 2018 Nov;57(11):1309-1315. doi: 10.1007/s00120-018-0789-x.
5
Immune mechanisms mediating abscopal effects in radioimmunotherapy.介导放射性免疫治疗远隔效应的免疫机制。
Pharmacol Ther. 2019 Apr;196:195-203. doi: 10.1016/j.pharmthera.2018.12.002. Epub 2018 Dec 5.
6
Immune checkpoint inhibitors with radiotherapy and locoregional treatment: synergism and potential clinical implications.免疫检查点抑制剂联合放疗及局部区域治疗:协同作用及潜在临床意义
Curr Opin Oncol. 2015 Nov;27(6):445-51. doi: 10.1097/CCO.0000000000000225.
7
PD-1 Restrains Radiotherapy-Induced Abscopal Effect.程序性死亡蛋白1抑制放射治疗诱导的远隔效应。
Cancer Immunol Res. 2015 Jun;3(6):610-9. doi: 10.1158/2326-6066.CIR-14-0138. Epub 2015 Feb 19.
8
Radiotherapy and checkpoint inhibitors: a winning new combination?放射疗法与检查点抑制剂:一种成功的新组合?
Ther Adv Med Oncol. 2018 Apr 11;10:1758835918768240. doi: 10.1177/1758835918768240. eCollection 2018.
9
Current clinical trials testing combinations of immunotherapy and radiation.目前正在进行免疫疗法与放射疗法联合应用的临床试验。
Semin Radiat Oncol. 2015 Jan;25(1):54-64. doi: 10.1016/j.semradonc.2014.07.003.
10
Preclinical Rationale and Clinical Considerations for Radiotherapy Plus Immunotherapy: Going Beyond Local Control.放射治疗联合免疫治疗的临床前理论依据与临床考量:超越局部控制
Cancer J. 2016 Mar-Apr;22(2):130-7. doi: 10.1097/PPO.0000000000000181.

引用本文的文献

1
mRNA Vaccines in Cancer Immunotherapy: Recent Advances, Clinical Translation, and Future Perspectives.癌症免疫治疗中的mRNA疫苗:最新进展、临床转化及未来展望
Curr Med Sci. 2025 Sep 15. doi: 10.1007/s11596-025-00112-5.
2
Immunotherapy combined with radiotherapy for advanced non-small cell lung cancer: Current status and challenge (Review).免疫疗法联合放疗治疗晚期非小细胞肺癌:现状与挑战(综述)
Oncol Lett. 2025 Aug 4;30(4):469. doi: 10.3892/ol.2025.15215. eCollection 2025 Oct.
3
The Impact of T-cell Exhaustion Dynamics on Tumour-Immune Interactions and Tumour Growth.T细胞耗竭动态对肿瘤-免疫相互作用及肿瘤生长的影响
Bull Math Biol. 2025 Apr 2;87(5):61. doi: 10.1007/s11538-025-01433-1.
4
Radiotherapy is enhanced by CPH:SA IL-1α microparticles in a murine HNSCC tumor model.在小鼠头颈部鳞状细胞癌肿瘤模型中,CPH:SA白细胞介素-1α微粒增强了放射治疗效果。
BMC Cancer. 2025 Apr 1;25(1):588. doi: 10.1186/s12885-025-13995-3.
5
Histological confirmation and radiotherapy facilitate continuation of epcoritamab in a patient with tumor flare reaction.组织学确认和放射治疗有助于在一名发生肿瘤flare反应的患者中继续使用epcoritamab。
Int J Hematol. 2025 Mar 29. doi: 10.1007/s12185-025-03979-1.
6
Radiation-Enhanced AF1q Moves Center Stage as a Key Driver to Favorable Tumor Stage in Rectal Cancer Patients.辐射增强的AF1q成为直肠癌患者肿瘤分期良好的关键驱动因素并登上中心舞台。
Cancer Med. 2025 Mar;14(5):e70658. doi: 10.1002/cam4.70658.
7
Intra-Tumoral Lymphocytic Infiltration Is Associated with Favorable Prognosis in Suboptimal Surgery in High-Grade Serous Ovarian Carcinoma.肿瘤内淋巴细胞浸润与高级别浆液性卵巢癌次优手术患者的良好预后相关。
Diagnostics (Basel). 2025 Feb 10;15(4):422. doi: 10.3390/diagnostics15040422.
8
Timing Anti-PD-L1 Checkpoint Blockade Immunotherapy to Enhance Tumor Irradiation.选择抗程序性死亡配体1(PD-L1)检查点阻断免疫疗法的时机以增强肿瘤放疗效果。
Cancers (Basel). 2025 Jan 24;17(3):391. doi: 10.3390/cancers17030391.
9
Neoadjuvant immunotherapy for DNA mismatch repair proficient/microsatellite stable non-metastatic rectal cancer: a systematic review and meta-analysis.DNA错配修复功能正常/微卫星稳定的非转移性直肠癌新辅助免疫治疗:一项系统评价和荟萃分析
Front Immunol. 2025 Jan 27;16:1523455. doi: 10.3389/fimmu.2025.1523455. eCollection 2025.
10
Role of immunotherapy in the overall survival of gastrointestinal cancer patients with liver metastases.免疫疗法在伴有肝转移的胃肠道癌患者总生存中的作用。
Hepat Oncol. 2024 Dec 31;11(1):2403323. doi: 10.1080/20450923.2024.2403323. Epub 2024 Sep 27.

本文引用的文献

1
Long-Term Clinical Responses of Neoadjuvant Dendritic Cell Infusions and Radiation in Soft Tissue Sarcoma.新辅助树突状细胞输注与放疗对软组织肉瘤的长期临床反应
Sarcoma. 2015;2015:614736. doi: 10.1155/2015/614736. Epub 2015 Dec 31.
2
Phase 2 Randomized Controlled Trial of Radiation Therapy Plus Concurrent Interferon-Alpha and Retinoic Acid Versus Cisplatin for Stage III Cervical Carcinoma.放疗联合干扰素-α和维甲酸与顺铂治疗 III 期宫颈癌的随机对照 2 期临床试验。
Int J Radiat Oncol Biol Phys. 2016 Jan 1;94(1):102-110. doi: 10.1016/j.ijrobp.2015.09.040.
3
A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab.对接受伊匹单抗治疗的转移性黑色素瘤患者放疗后远隔效应的系统评价。
Oncoimmunology. 2015 May 28;4(11):e1046028. doi: 10.1080/2162402X.2015.1046028. eCollection 2015 Nov.
4
Radiation and checkpoint blockade immunotherapy: radiosensitisation and potential mechanisms of synergy.放疗与免疫检查点抑制剂治疗:增敏作用及协同作用的潜在机制。
Lancet Oncol. 2015 Oct;16(13):e498-509. doi: 10.1016/S1470-2045(15)00007-8.
5
In situ vaccination by radiotherapy to improve responses to anti-CTLA-4 treatment.通过放射疗法进行原位疫苗接种以改善对抗CTLA-4治疗的反应。
Vaccine. 2015 Dec 16;33(51):7415-7422. doi: 10.1016/j.vaccine.2015.05.105. Epub 2015 Jul 3.
6
Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model.放射疗法与免疫细胞因子L19-IL2联合应用:在自然杀伤细胞依赖的肿瘤模型中的相加效应
Radiother Oncol. 2015 Sep;116(3):438-42. doi: 10.1016/j.radonc.2015.06.019. Epub 2015 Jun 29.
7
Local radiotherapy and granulocyte-macrophage colony-stimulating factor to generate abscopal responses in patients with metastatic solid tumours: a proof-of-principle trial.局部放疗和粒细胞-巨噬细胞集落刺激因子引发转移性实体瘤患者的远隔效应:一项原理验证试验。
Lancet Oncol. 2015 Jul;16(7):795-803. doi: 10.1016/S1470-2045(15)00054-6. Epub 2015 Jun 18.
8
Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.L19-IL2/L19-TNF瘤内给药用于III期或IVM1a期黑色素瘤患者:一项II期研究的结果
Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14.
9
Clinical applications of PD-1-based therapy: a focus on pembrolizumab (MK-3475) in the management of melanoma and other tumor types.基于PD-1的疗法的临床应用:聚焦派姆单抗(MK-3475)在黑色素瘤及其他肿瘤类型治疗中的应用
Onco Targets Ther. 2015 Apr 22;8:929-37. doi: 10.2147/OTT.S53164. eCollection 2015.
10
Ablative Tumor Radiation Can Change the Tumor Immune Cell Microenvironment to Induce Durable Complete Remissions.消融性肿瘤放疗可改变肿瘤免疫细胞微环境以诱导持久的完全缓解。
Clin Cancer Res. 2015 Aug 15;21(16):3727-39. doi: 10.1158/1078-0432.CCR-14-2824. Epub 2015 Apr 13.